UNSPSC 51362510: Etodroxizine maleate

This classification denotes a sedative and hypnotic with the molecular formula C23H31CLN2O3.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7P7N107PNA. European Medicines Agency schedules etodroxizine maleate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02044MIG. Most nations, for tariff and trade purposes, schedule etodroxizine maleate under HS 29335995 and SITC 51576. As of Q4 2014, ETODROXIZINE MALEATE remains US FDA's Preferred Term for this commodity.

SMILES: C1CCC(CC1)C(C2CCC(CC2)CL)N3CCN(CC3)CCOCCOCCO.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51362510 Etodroxizine maleate is a Commodity code that in practice encompasses pharmaceutical procurement by state and local health authorities, though the recent state and local opportunities tagged under this code show little direct activity in etodroxizine specifically. Instead, solicitations have centered on naloxone and drug deactivation systems, generic multi-source pharmaceuticals and OTC products through cooperative purchasing, and direct-to-manufacturer prescription programs. State and local buyers under codes in this family include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances that aggregate demand across participating jurisdictions. The Seminole County, Florida procurement (IFB60459723LAS, posted June 30, 2026) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP (S1070000015802, posted January 20, 2026, due March 26, 2026) established contracts for generic multi-source pharmaceuticals and OTC products across state and local facilities in Minnesota, Oregon, and participating members; and the Texas Health and Human Services Commission issued an RFI (HHS0017013, posted April 3, 2026) to explore direct-to-manufacturer prescription fulfillment models. These solicitations reveal that state and local governments buy pharmaceuticals through a mix of direct procurements, cooperative purchasing vehicles with established wholesaler networks, and exploratory market-intelligence processes before formal contracting.

Geographic activity centers on Florida, Texas, and the MMCAP member states (Minnesota and Oregon). Issuing bodies are predominantly state health departments and multistate alliances rather than municipal or county agencies outside of community health initiatives. The code shows active procurement in generic and OTC pharmaceutical categories with emphasis on supply chain compliance (cGMP, DSCSA certification), authorized wholesaler relationships, and pricing models weighted heavily on competitiveness (75 percent of evaluation in the MMCAP RFP). Vendors responding in this space face requirements for comprehensive insurance coverage, E-Verify compliance, and adherence to federal environmental and pharmaceutical regulations, with some contracts potentially funded through FEMA or state health initiatives. The current activity suggests moderate demand for pharmaceutical supply agreements under consolidated procurement frameworks rather than single-jurisdiction spot buys.